Enthera Pharmaceuticals raised a total financing of €35 million from Roche Venture Fund, Sofinnova Partners and AbbVie Ventures
Enthera Pharmaceuticals, a Milan, Italy-based biotech company developing disease-modifying biologics, announced securing a total financing of €35 million ($42.4M).
Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
Enthera Pharmaceuticals was in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca D’Addio.
The Company is the first spin-off of the Italian biotech accelerator BiovelocITA, founded by Sofinnova Partners, Silvano Spinelli and Gabriella Camboni, which provided the initial seed fund.
A seed extension was financed in 2018 by Sofinnova Partners, JDRF T1D fund and the other existing investors.